Abstract Details
Activity Number:
|
235
|
Type:
|
Topic Contributed
|
Date/Time:
|
Monday, August 5, 2013 : 2:00 PM to 3:50 PM
|
Sponsor:
|
Biometrics Section
|
Abstract - #308990 |
Title:
|
How Blind Should the Investigators and Sponsors Be?
|
Author(s):
|
James Neaton*+
|
Companies:
|
University of Minnesota
|
Keywords:
|
DSMB ;
clinical trial ;
interim monitoring
|
Abstract:
|
It is generally accepted that Data and Safety Monitoring Boards (DSMBs) should be the only group with access to interim safety and efficacy summary data comparing treatments in a clinical trial. However, there are circumstances in which aggregate outcome data may be needed by investigators or sponsors conducting the trial. For example, pooled outcome data may be needed for sample size re-estimation and for determining the closing date of an event drive trial. In addition, if the aim of the trial is to determine the effect of an intervention which modifies a risk factor or blood marker on clinical outcomes, investigators may want access to interim summaries of changes in the risk factor in order to assess whether trial goals are being met and adherence to the intervention. In some cases, it may even be necessary to share interim treatment comparisons due to concerns about safety or to counteract the findings of another trial. Case examples are used to illustrate situations where interim information might be considered and how it might be done.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2013 program
|
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.